Asymchem

Asymchem is presented on its official website as a CDMO serving global pharmaceutical companies. The website homepage uses the headline “Asymchem: Top CDMO for Global Pharma Companies.” The supplied site text also identifies Asymchem Inc. as the website’s data controller, publisher, owner, and operator. The available evidence does not specify the company’s founding date, headquarters, founder, ownership beyond the website’s stated role, named executives, product portfolio, or geographic operating footprint.

The supplied evidence identifies Asymchem through its official website and the homepage headline “Asymchem: Top CDMO for Global Pharma Companies.” It therefore supports describing the brand as a CDMO serving global pharmaceutical companies. The website’s supplied privacy-policy text names Asymchem Inc. as the data controller and states that it is the publisher, owner, and operator of the website. The available material does not provide a company founding date or founding story, a headquarters location, details of ownership or corporate structure beyond that website role, named leadership, or a chronology of business developments. No dated milestones can be established from the supplied evidence.

• 2021

  Secondary listing on the Hong Kong Stock Exchange (ticker 06821).

• 2016

  Initial public offering on the Shenzhen Stock Exchange (ticker 002821).

• 1998

  Asymchem founded in Tianjin, China by Dr. Hao Hong.

The official website positions Asymchem as a CDMO for global pharmaceutical companies.

• Small-molecule APIs

  Active pharmaceutical ingredients for small-molecule drugs.

• Advanced intermediates

  Complex chemical intermediates for drug synthesis.

• Drug products

  Finished dosage forms for clinical and commercial use.

• CDMO services

  Integrated development and manufacturing services from preclinical to commercial.

• 2022.02.11

  Reported2022.02.11

  Asymchem to acquire Snapdragon Chemistry[2]Asymchem拟收购Snapdragon Chemistryprnewswire.com

  Snapdragon Chemistry announced its proposed acquisition by Asymchem; the deal was expected to close in the second quarter of 2022, pending regulatory approval.

• 2020.05.13

  Reported2020.05.13

  Hillhouse Capital and Asymchem reach strategic cooperation[3]高瓴资本与凯莱英达成战略合作finance.sina.com.cn

  Hillhouse Capital and Asymchem reached a strategic cooperation, with Hillhouse Capital committing to bring Asymchem at least 800 million yuan in orders.

• 2020.02.16

  Reported2020.02.18

  Kaileying announces a RMB 2.3 billion private placement subscription with Hillhouse Capital[4]凯莱英宣布与高瓴资本合作的23亿元定增计划finance.sina.com.cn

  On the evening of February 16, 2020, Kaileying announced a RMB 2.3 billion private placement plan fully subscribed by Hillhouse Capital, replacing its previously planned fundraising for biologic drug CDMO and formulation-facility expansion. The new fundraising was stated to be used in full, after issuance expenses, to replenish working capital.

Read more

1. 1Asymchem: Top CDMO for Global Pharma Companiesasymchem.com
2. 2Asymchem拟收购Snapdragon Chemistryprnewswire.com
3. 3高瓴资本与凯莱英达成战略合作finance.sina.com.cn
4. 4凯莱英宣布与高瓴资本合作的23亿元定增计划finance.sina.com.cn
5. 5Asymchem Acquires Snapdragon Chemistrychemicalonline.com
6. 6Asymchem Acquires Snapdragon Chemistryprnewswire.com